Stockscreener 앱 받기
255.96
2.55%
6.37
시간 외 거래:
256.60
0.64
+0.25%
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Form 4 Alnylam Pharmaceuticals Inc For: 27 September - Investing.com India
Form 4 Alnylam Pharmaceuticals Inc For: 27 September By Investing.com - Investing.com Australia
Alnylam Needs Stronger AMVUTTRA Execution To Justify More Upside (NASDAQ:ALNY) - Seeking Alpha
Cambridge biotech co-founded by Alnylam founder Maraganore files for IPO - The Business Journals
Endpoints 11: Forget Alnylam or The Medicines Company. Corsera is Maraganore and Meanwell’s biggest bet - Endpoints News
The next Alnylam? RNAi biotech City Therapeutics files for IPO - Endpoints News
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price Today: $246.55 - Pluang
Alnylam Pharmaceuticals (ALNY) Short Interest & Short Float | Updated Sep 2026 $ALNY - MarketBeat
Alnylam Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Greenstreet Yvonne - moomoo.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Alnylam Pharmaceuticals (ALNY) Misses Q2 Earnings and Revenue Estimates - Eastern Progress
ALNY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $455 - GuruFocus
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $455 - moomoo.com
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Leader with a 55% Upside Potential - DirectorsTalk Interviews
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook - Yahoo Finance
Will RNAi Market Growth Change Alnylam Stock's Narrative? - simplywall.st
Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial - TradingView
Needham Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $357 - Moomoo
Alnylam Pharmaceuticals, Inc. RNAi Roundtable Call Transcript - gurufocus.com
Alnylam Pharmaceuticals (ALNY) Highlighted As An Oligonucleotide Therapeutics Leader Through 2035 - simplywall.st
Is Alnylam (ALNY) Quietly Repricing Its RNAi Risk Profile Amid Oligonucleotide Market Optimism? - finance.yahoo.com
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture - finance.yahoo.com
Alnylam Pharmaceuticals Inc (WBO:ALNY) Competitors 2026 - gurufocus.com
Alnylam Pharmaceuticals, Inc. at Morgan Stanley Global Healthcare Conference Transcript - gurufocus.com
Alnylam Pharmaceuticals (ALNY) Stock Analysis: A 49% Potential Upside Amidst Biotech Innovations - DirectorsTalk Interviews
Alnylam Pharmaceuticals (ALNY) Gains Attention After Fresh RNAi Data, Is It 33% Undervalued? - simplywall.st
If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today - Benzinga
Diluted earnings per share (diluted EPS) of Alnylam Pharmaceuticals, Inc – VIE:ALNY - TradingView
ETFs Investing in Alnylam Pharmaceuticals, Inc Stocks - TradingView
Why Alnylam Pharmaceuticals (ALNY) Stock Is Down Today - quiverquant.com
Best Biotech Stocks To Add to Your WatchlistSeptember 10th - MarketBeat
Here’s Why Alnylam Pharmaceuticals (ALNY) Declined - Yahoo Finance
Understanding the Setup: (ALNY) and Scalable Risk - Stock Traders Daily
ALNY Maintained by Jefferies -- Price Target Raised to $260 - GuruFocus
Alnylam at Wells Fargo conference: TTR growth stays on track By Investing.com - Investing.com South Africa
Alnylam at Wells Fargo conference: TTR growth stays on track - Investing.com
Alnylam Pharmaceuticals, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Onpattro Market Analysis Reveals Trends in Changing Industry Demand - openPR.com
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A 39% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
Alnylam Pharmaceuticals (ALNY) Could Be 39% Undervalued On Fresh ESC 2026 Data - simplywall.st
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth in Biotech - ChartMill
ALNY Stock Climbs As Analysts Turn Bullish After ESC Data - StocksToTrade
ALNY Stock Rebounds As Analysts Back RNAi Momentum - timothysykes.com
ALNY Stock Rebounds As Analysts Back RNAi Pipeline Strength - StocksToTrade
Alnylam Pharmaceuticals Inc Stock (ALNY) Moved Up by 7.90% on Sep 2: Facts Behind the Movement - TradingKey
Alnylam Pharmaceuticals Gains as Investors Digest Fresh ESC Data and Upcoming Conference Appearances - Moomoo
Alnylam Pharmaceuticals gains as investors digest fresh ESC data and upcoming conference appearances - Quiver Quantitative
Alnylam to Webcast Presentations at Upcoming September Investor Conferences - Business Wire
Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Alnylam Pharma (ALNY) - The Globe and Mail
Expanded RNAi Cardio Data Might Change The Case For Investing In Alnylam Pharmaceuticals (ALNY) - simplywall.st
Alnylam stock maintained at Buy by TD Cowen on silencing data - Investing.com Canada
Alnylam Pharmaceuticals (ALNY) Investor Outlook: Exploring a 56% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Alnylam data support Amvuttra across ATTR patient groups, advance hypertension drug case (ALNY:NASDAQ) - Seeking Alpha
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings - Yahoo Finance
Alnylam drops as AstraZeneca posts full trial results for failed heart drug - Seeking Alpha
Why Everyone Is Watching Alnylam Pharmaceuticals (ALNY) Today - simplywall.st
ALNY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alnylam Pharmaceuticals, Inc. - globenewswire.com
Alnylam Pharmaceuticals (ALNY) Stock Looks Cheap After A 47% Fall Yet Rich On Earnings - Yahoo Finance
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026 - businesswire.com
Is Alnylam (ALNY) Turning Expanded HELIOS-B and Zilebesiran Data Into Durable Cardiovascular Leadership? - Yahoo Finance
Enterprise value to revenue forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY - TradingView
0.24%
0.14%
자본화:
|
볼륨(24시간):